116574-72-2

Basic information

• Product Name: 3-(METHOXYMETHYL)PIPERIDINE
• Synonyms: CHEMBRDG-BB 4002971;3-(METHOXYMETHYL)PIPERIDINE;ASDI-INTER 500020499;OTAVA-BB 1147286;piperidine, 3-(methoxymethyl)-;3-(methoxymethyl)piperidine(SALTDATA: HCl)
• CAS NO: 116574-72-2
• Molecular Formula: C₇H₁₅NO
• Molecular Weight: 129.2
• Mol File: 116574-72-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 168℃
• Flash Point: 60℃
• Appearance: /
• Density: 0.882
• Vapor Pressure: 1.67mmHg at 25°C
• Refractive Index: 1.425
• CAS DataBase Reference: 3-(METHOXYMETHYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(METHOXYMETHYL)PIPERIDINE(116574-72-2)
• EPA Substance Registry System: 3-(METHOXYMETHYL)PIPERIDINE(116574-72-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 116574-72-2(Hazardous Substances Data)

Usage

General Description

3-(Methoxymethyl)piperidine is a chemical compound with the molecular formula C8H17NO. It is a piperidine derivative with a methoxymethyl functional group attached to the third carbon atom of the piperidine ring. 3-(METHOXYMETHYL)PIPERIDINE is commonly used as a building block in organic synthesis and pharmaceutical research. It is known for its potential as a precursor in the synthesis of various bioactive compounds and drug molecules. Its structure and properties make it useful in the development of new pharmaceuticals, especially in the field of central nervous system disorders and analgesics. Additionally, 3-(methoxymethyl)piperidine is also used in the manufacture of specialty chemicals and agrochemicals.

InChI:InChI=1/C7H15NO/c1-9-6-7-3-2-4-8-5-7/h7-8H,2-6H2,1H3

Upstream product

• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 868065-26-3 t-butyl 3-(methoxymethyl)piperidine-1-carboxylate 

Relevant articles and documents

Ruthenium-catalyzed α-(hetero)arylation of saturated cyclic amines: Reaction scope and mechanism

Transition-metal-catalyzed sp3 C-H activation has emerged as a powerful approach to functionalize saturated cyclic amines. Our group recently disclosed a direct catalytic arylation reaction of piperidines at the α position to the nitrogen atom. 1-(Pyridin-2-yl)piperidine could be smoothly α-arylated if treated with an arylboronic ester in the presence of a catalytic amount of [Ru3(CO)12] and one equivalent of 3-ethyl-3-pentanol. A systematic study on the substrate and reagent scope of this transformation is disclosed in this paper. The effect of substitution on both the piperidine ring and the arylboronic ester has been investigated. Smaller (pyrrolidine) and larger (azepane) saturated ring systems, as well as benzoannulated derivatives, were found to be compatible substrates with the α-arylation protocol. The successful use of a variety of heteroarylboronic esters as coupling partners further proved the power of this direct functionalization method. Mechanistic studies have allowed for a better understanding of the catalytic cycle of this remarkable transformation featuring an unprecedented direct transmetalation on a RuII-H species. Copyright

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.